Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.
Carmen Wing Han ChanBernard M H LawWinnie Kwok Wei SoKa Ming ChowMary Miu-Yee WayePublished in: Journal of cancer research and clinical oncology (2020)
Pharmacogenomics could play important roles in mediating the advancement of tamoxifen-based adjuvant therapies. Research efforts should be directed towards the exploration of further SNPs of CYP2D6 that affect tamoxifen metabolism, as well as epigenetic changes in CYP2D6, enabling the design of precision medicine and confirming clinical validity in the use of pharmacogenomics for tamoxifen.